We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -0.22% | 44.50 | 44.50 | 45.00 | 45.50 | 43.25 | 44.75 | 4,370,117 | 16:35:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.24 | 126.92M |
TIDMAVCT
Avacta Group PLC
21 March 2017
Hardman Research: Low response would be positive!
Low response would be positive!: Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. During 2016, Avacta made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. During coming weeks the company is expected to report on the next step in the pre-clinical development process: whether or not Affimer scaffolds are immunogenic. A positive outcome would be a low immune response rate.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/avacta-documents/21.03.17-low-response-would-be-positive!.pdf
Hot Features
Premium
To contact us: Contacts:
Hardman & Co Dr Martin Hall
11/12 Tokenhouse mh@hardmanandco.com
Yard Dr Dorothea Hill
London dmh@hardmanandco.com
EC2R 7AS Dr Gregoire Pave
gp@hardmanabdco.com
Telephone: +44 20 7929 3399
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADBLFLDXFXBBX
(END) Dow Jones Newswires
March 21, 2017 03:15 ET (07:15 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
